Amantadine Reduces Mania in Borna Disease Virus-Infected Non-Psychotic Bipolar Patients

 

 Buy Article Permissions and Reprints

This study investigated the clinical use and safety of amantadine in acute mania in an on-off-on design. Amantadine was augmented (200 mg/day) to pre-treatment strategies for 6 days, stopped for 6 days, and administered for another 6 days (on-off-on) in 10 manic inpatients. Manic symptoms were reduced in the first study period (on) by 45.8% [Young Mania Rating Scale (YMRS)]. Eight patients also finished the second period (off) which was not paralleled by any further reduction of mania. The third study period (on) was finished by seven patients with a further decrease of about 61.5%. The overall reduction from baseline after 18 days was 79.2% in this group. Amantadine augmentation reduced severe hypomania and moderate mania in BDV-infected bipolar I or II patients and was very well tolerated, especially no psychotic symptoms were observed.

References

• 1 Bode L, Dietrich DE, Ludwig H. In: Licinio J, Wong ML, editors. Biology of depression. Weinheim: Wiley-VCH 2005: 583-616
• 2 Bode L, Ludwig H. Borna disease virus infection, a human mental-health risk.  Clin Microbiol Rev. 2003;  16 534-545
  CrossrefPubMedGoogle Scholar
• 3 Bode L, Auer A, Dietrich DE, Ludwig H. Abstract 4th IFMAD. 2003;  , Available from http://www.aim-internationalgroup.com/2003/ifmad
  PubMed
• 4 Bode L, Dürrwald R, Rantam FA, Ferszt R, Ludwig H. First isolates of infectious human Borna disease virus from patients with mood disorders.  Mol Psychiatry. 1996;  1 200-212
  PubMedGoogle Scholar
• 5 Bode L, Zimmermann W, Ferszt R, Steinbach F, Ludwig H. Borna disease virus genome transcribed and expressed in psychiatric patients.  Nat Med. 1995;  1 232-236
  PubMedGoogle Scholar
• 6 Torre JC De la, Bode L, Carbone KM. et al .In: van Regenmortel MHV, Fauquet CM, Bishop DHL, editors. Virus Taxonomy. New York: Academic Press 2000: 531-538
• 7 Dietrich DE, Bode L, Spannhuth CW, Lau T, Huber TJ, Brodhun B, Ludwig H, Emrich HM. Amantadine in depressive patients with Borna disease virus (BDV) infection: an open trial.  Bipolar Disord. 2000;  2 65-70
  CrossrefPubMedGoogle Scholar
• 8 Flower R, Ludwig H. Presence of Borna disease virus (BDV)-specific structural components in human blood plasma.  J Clin Virol. 2006;  36 312-313
  CrossrefPubMedGoogle Scholar
• 9 Hornig M, Solbrig M, Horscroft N, Weissenböck H, Lipkin WI. Borna disease virus infection of adult and neonatal rats: models for neuropsychiatric disease.  Curr Top Microbiol Immunol. 2001;  253 157-177
  PubMedGoogle Scholar
• 10 Ikuta K, Ibrahim MS, Kobayashi T, Tomonaga K. Borna disease virus and infection in humans.  Front Biosci. 2002;  7d 470-495
  PubMedGoogle Scholar
• 11 Nakamura Y, Takahashi H, Shoya Y, Nakaya T, Watanabe M, Tomonaga K, Iwahashi K, Ameno K, Momiyama N, Taniyama H, Sata T, Kurata T, Torre JC de la, Ikuta K. Isolation of Borna disease virus from human brain tissue.  J Virol. 2000;  74 4601-4611
  CrossrefPubMedGoogle Scholar
• 12 Ohlmeier MD, Sieg S, Emrich HM, Dietrich DE. Amantadine in acute bipolar mania.  Aust N Z J Psychiatry. 2007;  41 194
  PubMedGoogle Scholar
• 13 Wolff T, Heins G, Pauli G, Burger R, Kurth R. Failure to detect Borna disease virus antigen and RNA in human blood.  J Clin Virol. 2006;  36 309-311
  CrossrefPubMedGoogle Scholar

1 The author's opinion does not reflect the opinion of the Robert Koch Institute

Correspondence

Dr. M. D. Ohlmeier

Department of Psychiatry, Socialpsychiatry and Psychotherapy

Hannover Medical School (MHH)

Carl-Neuberg-Straße 1

30625 Hannover

Germany

Phone: +49/511/532/65 59

Fax: +49/511/532/24 15

Email: dietrich.detlef@mh-hannover.de